Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on December 8, 2022. The report addresses corporate governance changes effective immediately on the filing date.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and contains no financial performance data.

Material Changes

The primary material change reported is the appointment of Scott G. Davis to the Board of Directors. Mr. Davis was recently appointed as Chief Executive Officer, having previously served as President and Chief Operating Officer. His term as a director is set to expire at the 2023 Annual Meeting of Stockholders.

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The report confirms there are no undisclosed arrangements or family relationships influencing Mr. Davis's election, and he holds no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.

Investor Verification Checklist

  • Verify the exact effective date of Scott G. Davis's appointment as CEO and Director.
  • Confirm the date of the 2023 Annual Meeting of Stockholders to determine the expiration of Mr. Davis's director term.
  • Review the 2022 Proxy Statement (filed April 29, 2022) for Mr. Davis's full biography and prior compensation details.
  • Check subsequent filings for any financial updates, as this 8-K contains no financial metrics.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.